Expert Opinion on Pharmacotherapy

Article	Citations
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	37
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	36
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	33
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	32
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	30
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	29
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	29
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	29
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	28
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	28
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	26
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	26
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	24
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	24
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	23
Current treatment options for Mycobacterium marinum cutaneous infections	22
Bexagliflozin for type 2 diabetes: an overview of the data	21
The pharmacological treatment and management of hyperhidrosis	20
How useful is chemotherapy for atypical and anaplastic meningiomas?	20
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	19
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	19
Zanubrutinib for the treatment of chronic lymphocytic leukemia	19
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	19
Momelotinib in myelofibrosis	19
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	18

When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	18
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	18
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	18
Correction	18
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	18
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	18
Rise and fall of decongestants in treating nasal congestion related diseases	17
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?	16
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	14
Selecting optimal therapy in systemic mastocytosis: current state and future directions	14
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	13
Tirzepatide for overweight and obesity management	13
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	13
Treating pediatric aggressive behaviors and comorbid conditions	13
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	13
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	12
Upadacitinib in Crohn’s disease	12
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	12
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	12
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	12
Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review	12
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	11
Correction	11
Current pharmacological solutions for Behçet’s syndrome	11
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	11
Approved medications for opioid use disorder : current update	11
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	11
Current advancements in pharmacotherapy for cancer cachexia	11
An update on current pharmacotherapy for vulvar cancer	11
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	11
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	11
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	11
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	11
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	11
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	11
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	10
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	10
Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer	10
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	10
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	10
Use of glucagon-like polypeptide 2 analogs for intestinal failure	10
Drug treatment strategies for eosinophilic esophagitis in adults	10
Recent progress in the use of pharmacotherapy for endometrial cancer	10
An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection	10
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	10
The treatment of advanced lung adenocarcinoma with activating EGFR mutations	10
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	10
Advances with androgen deprivation therapy for prostate cancer	10
Evidence-based prescribing of medications for ADHD: where are we in 2023?	10
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	10

Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	10
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	10
Simnotrelvir as a potential treatment for COVID-19	10
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	10
Reassessing the role of aspirin in patients with coronary artery disease	9
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease	9
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	9
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	9
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	9
Advances in pharmacotherapy for neuroblastoma	9
The role of sulfonylureas in the treatment of type 2 diabetes	9
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	9
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	9
Pharmacological management of pituitary adenomas – what is new on the horizon?	9
Current status of intracavernosal injection therapy in erectile dysfunction	9
Modern pharmacotherapy guidance for treating alcohol use disorders	9
Pharmaceutical advances in the treatment of gastric adenocarcinoma	9
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	9
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	9
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	9
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	9
An overview of emergency pharmacotherapy for priapism	9
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	9
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	9
Advances in the pharmacotherapeutic management of refractory peptic ulcers	9
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	9
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	9
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	8
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	8
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	8
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	8
Using adjuvant pharmacotherapy in the treatment of type 1 diabetes	8
Pharmacotherapy for artemisinin-resistant malaria	8
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	8
Recently approved and emerging drug options for migraine prophylaxis	8
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	8
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	8
Migraine in multiple sclerosis patients: potential links and treatment approach	8
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	8
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	8
The management of cardiovascular disease risk in patients with rheumatoid arthritis	8
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	8
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	8
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	8
Can NSAIDs and Acetaminophen Effectively Replace Opioid Treatment Options for Acute Pain?	7
Does opioid-based pharmacotherapy have a place in rheumatoid arthritis therapy?	7
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes	7
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	7
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	7
Pharmacological management of migraine: current strategies and future directions	7
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes	7
An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date	7
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	7
An update on the pharmacotherapy of gout	7
An update on the pharmacological management of acne vulgaris: the state of the art	7
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	7
Managing dyslipidemia in patients with Type 2 diabetes	7
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	7
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	7
Evaluating upadacitinib for the treatment of psoriatic arthritis	7
An update on antifungal resistance in dermatophytosis	7
Risk management of medication errors: a novel conceptual framework	7
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update	7
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	7
Pharmacological treatment for children with constipation: present and future	7
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	7
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	7
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	7
How do we address treating the negative symptoms of schizophrenia pharmacologically?	7
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease	7
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	7
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	7
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	7
Evaluating fostemsavir as a therapeutic option for patients with HIV	7
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	7
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	7
Addressing the long-term risks of administering antenatal steroids	7
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	6
Guidance for the pharmacological management of COVID-19 in the emergency setting	6
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	6

Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	6
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	6
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	6
A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, in Japan	6
Promising therapies for the treatment of acromegaly	6
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	6
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	6
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	6
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	6
Glasdegib for the treatment of acute myeloid leukemia	6
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	6
Azole resistance in Aspergillus species: promising therapeutic options	6
How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?	6
The evolving atopic dermatitis management landscape	6
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	6
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	6
Advances in pharmacotherapy for bronchiectasis in adults	6
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	6
Pharmacological management of heart failure: a patient-centred approach	6
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	6
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	6
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	6
Pharmacological strategies for improving the prognosis of glioblastoma	6
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	6
The pharmacological management of treatment-resistant depression: what does the future hold?	6
State-of-the-art and emerging antivirals for chronic hepatitis B infection	6
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	6
Advances in pharmacotherapy for diabetic foot osteomyelitis	6
Advances in the pharmacological management of acute myeloid leukemia in adults	6
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	6
Upadacitinib in Crohn’s disease: needs more insight	6
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	6
Can cannabinoids still play a role as pain medications?	6
The pharmacological management of alcohol-related cirrhosis: what’s new?	6
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	5
Management of non-alcoholic fatty liver disease in patients with sarcopenia	5
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs	5
Polypharmacology of carbonic anhydrase inhibitors and activators	5
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	5
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	5
Perspectives on the currently available pharmacotherapy for wet macular degeneration	5
Evolving therapeutic strategies for advanced hepatocellular carcinoma	5
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes	5
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults	5
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	5
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	5
Current factor IX replacement options for hemophilia B and the challenges ahead	5
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	5
Novel pharmacotherapy for drug-induced immune hemolytic anemia	5
How far are we from an approved drug for nonalcoholic steatohepatitis?	5
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	5
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections	5
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	5
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	5
Liposomal drug formulations for treatment of hematological malignancies	5
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature	5
An evaluation of the available pharmacotherapy for the treatment of hirsutism	5
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	5
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	5
The latest advances in the pharmacological management of endometriosis	5
Paxlovid as a potential treatment for long COVID	5
Montelukast as a potential treatment for COVID-19	5
An update on inclisiran for the treatment of elevated LDL cholesterol	5
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	5
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	5
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	5
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	5
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	5
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	5
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?	5
Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection	5
Ivosidenib in acute myeloid leukemia	5
Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?	5
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	5
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	5
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	5
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	5
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	5